Multiparticulate Systems of Meloxicam for Colonic Administration in Cancer or Autoimmune Diseases

Abstract

The aim of this research is the development of new colonic release systems of meloxicam (MLX) a non-steroidal anti-inflammatory drug (NSAIDs) with pH and time-dependent vehicles for cancer or autoimmune diseases. The colon has a higher pH than the rest of the gastrointestinal tract (GIT) and this can be used as a modified release strategy. Eudragit® polymers are the most widely used synthetic products in the design of colonic release formulations because they might offer mucoadhesiveness and pH-dependent release. Colonic delivery systems produced with pH-dependent and permeable polymers (FS-30D) or with pH-independent and low permeability polymers (NM-30D), must dissolve at a pH range of 6.0–7.0 to delay the release of the drug and prevent degradation in the GIT, before reaching the colon. The conditions prepared to simulate a gastrointestinal transit showed the CNM multiparticulate system, composed of Eudragit® NM and cellulose, as the best release option for MLX with a more sustained release with respect to the other formulations. CNM formulation followed Higuchi and First-order release kinetics, thus MLX release was controlled by a combination of diffusion and polymers swelling/eroding processes.

N -Arylacetamide derivatives of methyl 1,2-benzothiazine-3-carboxylate as potential drug candidates for urease inhibition

“…They are well-known non-steroidal anti-inflammatory drugs (NSAIDs) commercially available as oxicams [ 29 ]. Studies reveal that 1,2-benzothiazines exhibit wide pharmacological activities such as anti-inflammatory [ 30 ], calpain I inhibitors [ 31 ], anti-cancer [ 32 ], anti-microbial [ 33 ], analgesic [ 34 ], MAPK inhibitors [ 35 ], MAO inhibition [ 36 ], anti-arthritic [ 37 ], anti-oxidant [ 38 ], anti-viral [ 39 , 40 ], anti-diabetic [ 41 ], anti-convulsant [ 42 ] and anti-malarial [ 43 ]. Other applications include as herbicides and as dyestuff in industry [ 44 ].…”